West Pharmaceutical Services (WST) Free Cash Flow (2009 - 2026)

West Pharmaceutical Services (WST) has reported Free Cash Flow for 18 consecutive years, with $80.8 million the latest figure, recorded in Q2 2026.

• Quarterly Free Cash Flow fell 20.71% year-over-year to $80.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $436.9 million (up 27.01% YoY) and the FY2025 annual result came in at $468.9 million, up 69.65% from the prior year.
• Free Cash Flow improved to $80.8 million in Q2 2026 per WST's latest filing, from $47.2 million in the prior quarter.
• Over the last five years, Free Cash Flow for WST reached as high as $175.0 million in Q4 2025 and fell as low as $27.6 million in Q1 2024.
• A 5-year average of $96.0 million and a median of $96.3 million in 2023 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2022 — Free Cash Flow surged 151.18% — and 2024, when it sank 50.71%.
• Year by year, Free Cash Flow stood at $135.9 million in 2022, then dropped by 4.05% to $130.4 million in 2023, then slumped by 34.66% to $85.2 million in 2024, then surged by 105.4% to $175.0 million in 2025, then tumbled by 53.83% to $80.8 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered $80.8 million, $47.2 million, and $175.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.